2. The Cost of Depression in the Workplace
Charts showing the prevalence of depression in the workplace, as well as the cost in terms of lost hours and lost productivity.
Almost everyone agrees that depression is a disease that endangers millions of lives and livelihoods. It also costs businesses billions of dollars each year. But what should business do about its treatment? That's where the arguments begin. One approach favors "talk therapy" and medication with antidepressants, while the other relies on treatment that's more pharmaceutical than psychiatric. Plus: Declining coverage for behavioral health.
By Andy Meisler Comments 0 | Recommend 0
mployee
A, whose absences are increasing and whose work performance is deteriorating, is
urged by his supervisor to visit the company’s employee-assistance program. The
EAP counselor--a licensed psychologist--notices that A is distracted and
listless. His questions reveal that A is experiencing severe insomnia, feelings
of hopelessness and thoughts of suicide. The employee is referred to a
psychiatrist connected to the company’s health plan.
On his first hour-long visit, the psychiatrist delves
deeper into A’s background and symptoms. The physician asks whether A has a
family history of mental illness. He diagnoses clinical depression, prescribes
an antidepressant and explains that depression is an illness with roots in both
brain chemistry and life stresses. He tells A that modern antidepressants take
several weeks to "kick in" but are usually--though not always--effective. The
doctor also cautions that the drugs often have side effects, including
drowsiness, weight gain and sexual dysfunction. Over the next three months they
meet for an hour each week, 12 sessions, so that the psychiatrist can monitor
the medication, answer A’s questions and conduct a short, focused course of
psychotherapy.
Employee B, plagued by pain, fatigue and other symptoms,
sees her primary-care physician for a checkup. After a 15-minute appointment,
the physician finds nothing physically wrong and asks her to fill out a short
mental-health-oriented questionnaire. The form is faxed to a company
specializing in behavioral health care, which grades it and informs the
primary-care physician that the patient’s answers indicate clinical depression.
The physician calls B, visits with her briefly and prescribes an antidepressant.
A week later, B receives an early-evening phone call from
a counselor at the behavioral-health company who might be a social worker, a
nurse or an uncredentialed health-care worker. During the first call, the
counselor asks whether B is taking her medication and gauges her current state
of mind in a 10- to 15-minute visit. If it appears that B’s depression is
becoming dangerously worse, the counselor can ask for advice from his superiors.
The counselor makes three more semi-scripted phone calls over the next six
months. During that time, B is also mailed a series of six pamphlets explaining
the nature of depression, the effectiveness and drawbacks of antidepressants,
and other strategies for coping with the illness.
Both cases are hypothetical. But each represents the ideal
course of treatment espoused by one of two warring factions in the mental-health
industry. Along with the advent of managed care has come a decrease in relative
and absolute terms in the amount that employers contribute to their employees’
behavioral health care. From 1988 to 1997 the average dollar amount, adjusted
for inflation, dropped from $151.54 to $69.61 per employee per year and from 6.1
to 3.1 percent of total health-care expenditures. "And that trend has
continued," says Ed Hustead of The Hay Group, the consulting firm that conducted
the survey. The mental-health coverage experienced by Patient A, it’s been
calculated, will raise health-care premiums by as much as 5 percent. The
treatment received by Patient B, bundled together with similar programs for
conditions like heart disease, asthma and diabetes, will cost from $1 to $5 per
employee per month. Still, proponents insist that savings associated with
improved worker productivity will make it essentially "cost neutral." As a
workforce executive, which course of treatment would you consider to be more
effective for you or a coworker? Which would be more cost-effective for the
company? The answers are as complicated and elusive as the dangerous illness
behind them.
Fighting a stealth epidemic
These facts are not in dispute:
Depression is a widespread illness. According
to a recently published study in the Journal of the American Medical
Association, 16.2 percent of the U.S. adult population will experience
major depression at some time in their life; 6.6 percent suffered an episode in
the past year.
Depression is a major drain on business
productivity and profits. Another recent JAMA-published study calculated that
depressed workers cost their employers $44 billion each year: 19 percent of
that because of increased absenteeism but a surprising 81 percent because of "presenteeism"--defined
as employees who show up for work but perform at only a fraction of their
capabilities.
Depression is poorly diagnosed. For a variety
of reasons, including the stigma still attached to the disease, only 33 percent
of all depression sufferers, according to the same study, receive medication
for their disease.
Dr. Jerome Vaccaro, a psychiatrist and CEO of PacifiCare
Behavioral Health in Laguna Hills, California, says, "Yes, it’s badly
undertreated. Even psychiatrists and psychologists, when they see hopeless,
helpless patients, miss the diagnosis more than half the time. But we’ve got
data to show that we’re driving that figure down." Like similar companies
nationwide--including Wausau Benefits and Magellan Behavioral Health--PacifiCare
is a specialized mental-health subcontractor to larger health insurance
companies, assisting HMOs and PPOs in offering programs like the one used by
Patient B. "They’re practical, they work, and the best of them bring together
the best science of depression medicine," Vaccaro says. The plans cut
traditional paid-by-the-hour mental-health specialists--psychiatrists and
psychologists--out of the loop.
The American Association of Health
Plans reports that in 2001, 56.6 percent of health plans offered
disease-management programs for depression, a figure that jumped to 81.1
percent the following year.
Programs like PacifiCare’s are a 21st-century
addition to the movement toward disease management. Managed health is designed
to educate patients and give them more control over their treatment while
cutting down on the number of expensive office visits to primary care physicians
and specialists. For more than 15 years, disease-management programs have been
used to treat chronic conditions like cardiovascular disease, asthma and
diabetes--and their use for depression is increasing rapidly. The American
Association of Health Plans reports that in 2001, 56.6 percent of health plans
offered disease-management programs for depression, a figure that jumped to 81.1
percent the following year.
Not everyone views this development favorably. Many
experts say that depression, which affects the mind, shouldn’t be compared to
"physical" illnesses that affect less complicated and better-understood organs.
Among the most insidious aspects of depression, they emphasize, is that the
disease causes individuals to hide what many perceive to be a "shameful" illness
from others, and to believe with hyper-pessimistic certainty that no treatment
or recovery is possible. Most members of the mental-health community, according
to the positions of organizations like the American Psychological Association,
believe that an essential component of a treatment is extensive interaction
between and patient and a medical professional--the foundation of what disease
management aims to manage away. Dr. Norman Clemens, a professor of psychiatry at
Case Western Reserve University in Cleveland and chairman of the American
Psychiatric Association’s Committee on APA/Business relations, says, "There are
some fairly simple depressions that can be treated by a [primary care physician]
with medication, but the threshold for referral to a specialist should be very
low. This is a lethal disease. It’s foolish to save pennies when you could be
saving a life."
Dr. Stephen Heidel, a San Diego-based psychiatrist who has
an MBA as well as a medical degree and has designed and implemented EAPs for
local employers, says, "A questionnaire is not a diagnosis. A diagnosis is a
diagnosis." He says that a face-to-face meeting with a clinical psychiatrist,
trained to pick up subtle aspects of a patient’s expression, affect and body
language, is necessary before the appropriate treatment, if any, is begun. He
contends that harried primary doctors, whether they’ve been specially trained or
not, will tend to miss the signs of depression or, just as bad, pick up on them
and "take a shot" at treating patients themselves. As for proper treatment, he
says that the best results in treating depression come from combining drugs and
"talk" therapy. "That’s the gold standard," he says.
Jerome Vaccaro scoffs at this point of view. "Many
patients faced with this disease and the stigma attached to it will never agree
to be seen by a psychiatrist." They’ll only agree to be treated by their primary
care doctor, he says, "whom they already know and trust."
Psych war
The argument is part of a much larger and older dispute.
Until the early 1980s, health plans that paid for mental-health care spent most
of their money on patient hospitalizations and outpatient visits to
psychiatrists, psychologists and licensed social workers who conducted fairly
open-ended talk therapies. Toward the end of the 1980s, however, two important
events coincided: the advent of managed health care and the arrival of the first
medications such as Prozac that were truly effective and relatively free of side
effects.
Physicians began prescribing antidepressants. The
psychiatric and psychological communities discovered that shorter-range talk
therapies seemed to work pretty well in combination with drugs. A 2001 New
England Journal of Medicine study found that when used together,
antidepressants and cognitive therapy helped 85 percent of patients suffering
from chronic major depression. The success rate for patients treated with
cognitive therapy alone or drugs alone hovered around 50 percent. By the late
1990s, however, disease-management programs for depression began to proliferate.
The drugs-plus-talk advocates say that the patients who drop through the cracks
will cost companies far more in lost productivity than will be saved in
insurance premiums.
Add pressure from advocacy groups pushing for
"mental-health parity" in public and private health plans, and it’s obvious that
some kind of resolution is needed.
It may be coming. In June, a major JAMA-published study,
"The Epidemiology of Major Depressive Disorder," defined adequate treatment for
the disease as "either (1) at least four outpatient visits with any type of
physician for pharmacotherapy that included use of either an antidepressant or
mood stabilizer for a minimum of 30 days, or (2) at least eight outpatient
visits with any professional in the specialty mental health sector for
psychotherapy lasting a mean of at least 30 minutes."
And several weeks ago, President Bush’s New Freedom
Commission on Mental Health released its lengthy report. It didn’t set minimum
standards for treatment, or weigh in specifically on the battling approaches. It
did endorse reimbursements for e-health and telemedicine services and
recommended that the U.S. Department of Health and Human Services lead a review
of "how to best deliver and finance these services in consultation with private
payers, insurers, state agencies and other federal programs." Ultimately, of
course, it will be the marketplace--not politicians or even physicians--that
will decide.
Workforce Management, September 2003, pp.
57-60 --
Subscribe Now!
Andy Meisler is a WorkforceManagement staff writer. E-mail editors@workforce.com to comment.
Reproductions and distribution of the above article are strictly prohibited. To order reprints and/or request permission to use the article in full or partial format, please contact our Reprint Sales Manager at (732) 723-0569.
Comments
Guidelines: Comments that include profanity or personal attacks or other inappropriate comments or material will be removed
from the site. We will take steps to block users who violate any of our posting standards, terms of use or privacy policies
or any other policies governing this site. You are fully responsible for the content you post.